Publications by authors named "K Eric Drexler"
Background: Up to now, the optimal duration of immune checkpoint inhibitors (ICI) has not been evaluated in prospective studies. However, current clinical practice requires decisions to be made regarding the duration of ICI in complete responders.
Material And Methods: A survey was sent to 80 DeCOG skin cancer centers to assess how decisions are made on treatment duration of ICI in melanoma after having reached complete response, and staging intervals after ICI discontinuation.
Article Synopsis
- Granuloma annulare (GA) is a non-infectious skin condition that can become widespread in some patients; this study focused on those with disseminated GA in a German hospital.
- A total of 239 patients were studied, with 33 having confirmed disseminated GA, predominantly affecting women around the age of 57, and many reporting little to no symptoms.
- Treatment options included glucocorticoids and phototherapy, but only a small percentage achieved remission, highlighting the need for more effective clinical trials for new therapies.
With regard to excision of pigmented lesions for detection of malignant melanoma (MM), the number needed to treat (NNT) describes the number of melanocytic nevi that need to be biopsied/excised to detect one MM. The aim should be a low NNT. : Single-center data analysis, including dermatohistopathological records of all nevi and MM cases during 2004-2013 at the Department of Dermatology, University Hospital Regensburg (UKR), was performed.
View Article and Find Full Text PDFBackground: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through the modulation of coagulation and platelet activity. Both have been found to play an important role in the tumor microenvironment, tumor growth and metastasis.
View Article and Find Full Text PDFBackground: The US Department of Veterans Affairs, Department of Defense (VA/DoD) clinical guidelines recommend extended-release naltrexone (XR-NTX) as a treatment option for moderate-to-severe alcohol use disorder (AUD); however, contemporary real-world outcomes related to this guideline are lacking. This retrospective, observational, descriptive study examined treatment patterns and healthcare resource use (HCRU) among veterans with an AUD diagnosis who initiated XR-NTX.
Methods: Veterans with incident AUD who initiated XR-NTX between 8/2014 and 11/2018 were identified.